MCI Speech in Noise

Last updated: June 4, 2024
Sponsor: Dartmouth-Hitchcock Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mild Cognitive Impairment

Mental Disability

Alzheimer's Disease

Treatment

N/A

Clinical Study ID

NCT06102486
STUDY02002079
  • Ages 55-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. The investigators are also evaluating, within those with MCI, whether the hearing tests are associated with neurocognitive functioning. The investigators are interested in learning whether changes in cognition in those with MCI can be detected using tests of how the brain processes sound. The investigators hypothesize that participants with MCI will score worse on both hearing tests and neurocognitive tests than participants without MCI. Participants are asked to complete multiple types of hearing tests, take a series of neurocognitive tests, and complete a few questionnaires.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults diagnosed with or suspected to have MCI (for MCI group) or are cognitivelynormal (for Control group)

  • Absence of other risk factors that might affect CAP (Central Auditory Processing)performance (e.g., active ear infections, congenital developmental delay, severehearing loss)

  • Age 55-80

  • Normal hearing sensitivity (<40 dB HL Pure Tone Average (average of 500, 1000, 2000Hz) thresholds bilaterally

  • Normal middle ear function defined by tympanometry (0.3-2.0 ml)

  • Native English speaker

Exclusion

Exclusion Criteria:

  • Active ear infections or abnormal middle ear pathology

  • Other health condition prohibiting the completion of the CAP test battery

  • Mild to profound peripheral hearing loss (>40 dB (decibel) HL (hearing loss) PureTone Average (average of 500, 1000, 2000 Hz) bilaterally

  • Adults unable to consent

  • Individuals who are not yet adults (infants, children, teenagers)

  • Prisoners

  • History of CNS (Central Nervous System) disorder that might severely impactcognitive function (e.g., Alzheimer's disease, Parkinson's disease, multiplesclerosis, neurosyphilis, intracranial tumors, history of significant head traumawith loss of consciousness (≥30 min), and cerebrovascular disease)

  • Severe mental illness (e.g., schizophrenia, bipolar disorder)

  • Current, uncontrolled medical condition that could affect cognition (e.g.,hypertension)

  • History of substance use disorder within the (other than nicotine/caffeine)

  • Non-correctable severe hearing or vision loss

  • Use of "Cognition Enhancing Drugs"

  • Frequent, severe headaches (occasional headaches or migraines are fine)

Study Design

Total Participants: 70
Study Start date:
May 18, 2024
Estimated Completion Date:
December 02, 2025

Connect with a study center

  • Space Medicine Lab at Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire 03756
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.